Myelodysplastic Syndrome (MDS) & Chronic Myelomonocytic Leukemia (CMML)

**Higher Risk MDS**
- **HEMMDS0043**
  - Cellular and Humoral Modulation of Hemopoiesis
  - PI: Greenberg
  - Sponsor: Stanford University

**Lower Risk MDS + CMML**
- **HEMMDS0045**
  - Phase IIb Open Label Multi-Center Dose Optimization & Dose Expansion Study to Assess Safety & Efficacy of DFV870 in Adult Myeloid Diseases
  - PI: Greenberg
  - Sponsor: Novartis Pharmaceuticals Corporation
  - Priority 3

- **HEM0056**
  - Phase 1b/2 Safety & Efficacy of Enasidenib in MDS/Myelomonocytic Leukemia without IDH2 Mutation
  - PI: Zhang
  - Sponsor: Stanford University
  - Priority 1

- **HEMMDS0043**
  - Cellular and Humoral Modulation of Hemopoiesis
  - PI: Greenberg
  - Sponsor: Stanford University

- **HEMMDS0042**
  - Phase III
  - INCB000928 Monotherapy in Subjects w/ Anemia Due To Myelodysplastic Syndromes / Multiple Myeloma
  - PI: Shomali
  - Sponsor: Incyte Corporation
  - Priority 2

**Key**
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu